Tag Archives: AstraZeneca

Big Pharma’s Big Tuesday

What’s the opposite of Black Tuesday? White Tuesday? Golden Tuesday? Because today the stock market is a-flutter following the news that Novartis is to acquire GSK’s cancer drugs business, while selling its vaccines division to GSK. Add in speculation of a $100bn Pfizer bid for AstraZeneca and Valeant Pharmaceuticals and things are positively booming. As of lunchtime […]
Posted in Deals, Europe, Global, Strategy | Also tagged , , , , | Leave a comment

Outlook “Gloomy” for TB Investment

The approval last year of Johnson & Johnson’s (J&J) treatment for tuberculosis (bedaquiline) — at the time the first TB drug approval in 40 years — “remains an exception to the generally gloomy outlook” for investment in TB R&D, writes Andrew Ward in this week’s Financial Times.
Posted in Emerging Markets, Global, Strategy | Also tagged , , , , | Leave a comment

Bristol-Myers Squibb Sells Diabetes Business to AstraZeneca

Bristol-Myers Squibb has agreed to sell its global diabetes business that was part of its collaboration with AstraZeneca for $2.7 billion with potential regulatory- and sales-based milestone payments of up to $1.4 billion and will make royalty payments based on net sales through 2025. In addition, AstraZeneca will make payments of up to $225 million […]
Posted in Deals, Guest Blog | Also tagged , , | Leave a comment

Behind the China Bribery Scandals

The last few weeks have seen the media swamped with stories about the rampant bribery clawing the pharmaceutical industry in China. Big names were engulfed in the scandal, including GSK, AstraZeneca, Sanofi, Novartis, Eli Lilly, Novo Nordisk and UCB amongst others. Last month, four GSK executives were put under investigation for allegedly paying up to […]
Posted in Emerging Markets, Global, Guest Blog | Also tagged , , , , , , , , | Leave a comment

The Curious Case Of AstraZeneca v. ACE

by Mike Kelly and Andrew Dupre Insurance contracts are a language game that must be played very carefully, as AstraZeneca learned. From 2003 to 2012, AstraZeneca Plc was locked in one of the largest mass tort litigations in the United States, defending its blockbuster second generation atypical antipsychotic product Seroquel from allegations of failure-to-warn of […]
Posted in compliance, Europe, Guest Blog, leadership, Legal, Marketing, Regulatory, Safety, Sales, Strategy | Also tagged , , , , , , , | Leave a comment
  • Categories

  • Meta